Posted on 14/01/2010 in Pharmaceutical Company Product News Lundbeck and Teva have revealed their intentions to penetrate Europe's fifth-largest pharmaceutical market by releasing the therapy Azilect (rasagiline) in France.
The once-daily tablets are indicated for the treatment of Parkinson's disease both as initial monotherapy in the condition's early stages and as adjunct to levodopa in the later stages.
According to the firm, the European market value comprises almost 50 per cent of the global demand for Parkinson's disease treatments and is estimated at approximately 2.7 billion euros (2.41 billion pounds).
Stig Lokke Pedersen, executive vice-president of commercial operations at Lundbeck, said: "Azilect is the first and only product that has demonstrated effect on slowing clinical progression of Parkinson's disease and we are looking forward to providing it to the French market."
Last month, Lundbeck announced the positive results of two clinical trials into its schizophrenia therapy zicronapine.
Both studies indicated that the drug demonstrated noticeable statistical separation from placebo at 7 and 10 mg doses.Other news stories from 14/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
